Checkmate Pharmaceuticals, Inc. (NASDAQ:CMPI – Get Rating) major shareholder Global Strategic Fund I. Venbio sold 153,700 shares of the stock in a transaction dated Monday, May 2nd. The shares were sold at an average price of $10.38, for a total value of $1,595,406.00. Following the completion of the transaction, the insider now directly owns 2,652,133 shares of the company’s stock, valued at approximately $27,529,140.54. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Large shareholders that own at least 10% of a company’s stock are required to disclose their sales and purchases with the SEC.
Shares of NASDAQ CMPI opened at $10.37 on Thursday. The stock’s 50 day moving average price is $4.81 and its two-hundred day moving average price is $3.79. Checkmate Pharmaceuticals, Inc. has a 52-week low of $2.00 and a 52-week high of $10.48.
Checkmate Pharmaceuticals (NASDAQ:CMPI – Get Rating) last announced its quarterly earnings results on Tuesday, March 29th. The company reported ($0.62) earnings per share for the quarter. As a group, equities research analysts predict that Checkmate Pharmaceuticals, Inc. will post -3.14 EPS for the current fiscal year.
Several analysts have issued reports on the company. Zacks Investment Research upgraded Checkmate Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday. BTIG Research cut Checkmate Pharmaceuticals from a “buy” rating to a “neutral” rating in a research note on Wednesday, April 20th.
About Checkmate Pharmaceuticals (Get Rating)
Checkmate Pharmaceuticals, Inc, a clinical-stage biotechnology company, focuses on developing and commercializing novel therapeutics for the treatment of cancer. It develops CMP-001, which is in phase II clinical trial in combination with pembrolizumab to treat patients with PD-1 refractory melanoma; combination with nivolumab to treat patients with PD-1 naïve neoadjuvant melanoma; and treatment in patients with PD-1 refractory melanoma.
- Get a free copy of the StockNews.com research report on Checkmate Pharmaceuticals (CMPI)
- World Wresting Entertainment Stock is Hulking Up
- High-Yield Weyco Group Returns To Reasonable Levels
- MarketBeat Podcast: Alternative Investing Strategies Despite Market Volatility
- Limelight Networks Stock is a Speculative Turnaround Opportunity
- The Selloff In SiteOne Landscape Supply Is Overextended
Receive News & Ratings for Checkmate Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Checkmate Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.